WOODWORTH TG[au] - Search Results

Year	Number of Results
1987	1
1992	1
1993	4
1994	3
1995	2
1996	2
2000	1
2001	1
2003	2
2004	1
2005	4
2008	1
2009	1
2011	2
2012	1
2013	2
2014	2
2015	3
2016	2
2017	4
2018	1
2019	4
2020	2
2021	2
2023	0

1

Scleroderma renal crisis and renal involvement in systemic sclerosis.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Woodworth TG, et al. Nat Rev Nephrol. 2016 Nov;12(11):678-691. doi: 10.1038/nrneph.2016.124. Epub 2016 Sep 19. Nat Rev Nephrol. 2016. PMID: 27641135 Review.

2

Preface.

den Broeder AA, Woodworth TG. den Broeder AA, et al. Among authors: woodworth tg. Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):525-6. doi: 10.1016/j.berh.2015.09.008. Epub 2015 Nov 28. Best Pract Res Clin Rheumatol. 2015. PMID: 26697763 No abstract available.

3

We still don't know how to taper glucocorticoids in rheumatoid arthritis, and we can do better.

Volkmann ER, Rezai S, Tarp S, Woodworth TG, Furst DE. Volkmann ER, et al. Among authors: woodworth tg. J Rheumatol. 2013 Oct;40(10):1646-9. doi: 10.3899/jrheum.130019. J Rheumatol. 2013. PMID: 24085754 No abstract available.

4

Timely renal transplantation for scleroderma end-stage kidney disease patients can improve outcomes and quality of life.

Woodworth TG, Furst DE. Woodworth TG, et al. Ann Transl Med. 2019 Feb;7(3):60. doi: 10.21037/atm.2018.12.64. Ann Transl Med. 2019. PMID: 30906764 Free PMC article. No abstract available.

5

Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.

Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG. Strom TB, et al. Among authors: woodworth tg. Annu Rev Med. 1993;44:343-53. doi: 10.1146/annurev.me.44.020193.002015. Annu Rev Med. 1993. PMID: 8476255 Review.

6

Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules.

Strom TB, Kelley VR, Woodworth TG, Murphy JR. Strom TB, et al. Among authors: woodworth tg. Immunol Rev. 1992 Oct;129:131-63. doi: 10.1111/j.1600-065x.1992.tb01422.x. Immunol Rev. 1992. PMID: 1464418 Review. No abstract available.

7

Recombinant fusion toxins--a new class of targeted biologic therapeutics.

Woodworth TG, Nichols JC. Woodworth TG, et al. Cancer Treat Res. 1993;68:145-60. doi: 10.1007/978-1-4615-3076-3_8. Cancer Treat Res. 1993. PMID: 8105849 Review.

8

Challenges and progress in adverse event ascertainment and reporting in clinical trials.

Lassere MN, Johnson KR, Woodworth TG, Furst DE, Fries JF, Kirwan JR, Tugwell PS, Day RO, Brooks PM. Lassere MN, et al. Among authors: woodworth tg. J Rheumatol. 2005 Oct;32(10):2030-2. J Rheumatol. 2005. PMID: 16206364 Review.

9

Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy.

Woodworth TG, Furst DE. Woodworth TG, et al. Arthritis Res Ther. 2014 Jul 30;16(4):113. doi: 10.1186/ar4677. Arthritis Res Ther. 2014. PMID: 25166210 Free PMC article.

10

Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group.

Berthelsen DB, Woodworth TG, Goel N, Ioannidis JPA, Tugwell P, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Leong AL, Conaghan PG, Boers M, Shea BJ, Brooks PM, Simon LS, Furst DE, Christensen R; OMERACT Safety Working Group. Berthelsen DB, et al. Among authors: woodworth tg. Semin Arthritis Rheum. 2021 Jun;51(3):607-617. doi: 10.1016/j.semarthrit.2020.09.023. Epub 2021 Jan 9. Semin Arthritis Rheum. 2021. PMID: 33483129 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results